Advertisement


Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin

2016 ESMO Congress

Advertisement

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)



Related Videos

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)

Lung Cancer

Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial (Italian Language Version)

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–small cell lung cancer previously treated with chemotherapy and crizotinib.

Skin Cancer

Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)

Lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

Gastroesophageal Cancer
Gastrointestinal Cancer

Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version)

Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)

Advertisement

Advertisement




Advertisement